PPGN.SW

For PolyPeptide Group AG to rerate higher, the EBITDA Margin for H1 2026 needs to hit 15% or higher. This would demonstrate a clear trajectory towards the high-teens for the full year 2026, surpassing the 2025 reported 12.0% and potentially exceeding the current analyst consensus of 15.3% for the full year. Such a performance would also signal strong progress towards the company's mid-term outlook of approaching 25% EBITDA margin by 2028.

Achieving an EBITDA Margin of 15% or higher for H1 2026 would signal robust operational leverage and effective execution of growth strategies, particularly in the expanding GLP-1 market. This would validate the company's long-term profitability potential, enhance its competitive standing, and reinforce investor confidence in its intrinsic value, potentially driving the stock higher beyond the current acquisition valuation.

Development Revenue Growth needs to hit 30% or higher for the upcoming report. This would demonstrate continued strong momentum in its development pipeline, exceeding the company's overall 2026 revenue growth guidance of 20-25% and maintaining or surpassing its robust 29.9% growth from 2025.

This metric directly reflects the strength of PolyPeptide's pipeline and its ability to convert development projects into future commercial revenue, particularly in the high-growth GLP-1 space. Exceeding expectations would validate the bullish investment thesis, demonstrating strong demand for its CDMO services and justifying a higher valuation by showcasing robust long-term growth potential and competitive positioning.

For the stock to rerate higher, the final reported Total Revenue growth for H1 2026 needs to significantly exceed the already disclosed preliminary growth of 41.6% year-over-year, for example, reaching 45% or more. This would represent a substantial beat on the preliminary results and far surpass the company's full-year 2026 guidance of 20-25%.

Exceeding the preliminary H1 2026 revenue growth of 41.6% would signal even stronger demand for peptide-based APIs, especially in the high-growth GLP-1 market. This validates PolyPeptide's investments and competitive position, potentially driving upward revisions in the full-year outlook and boosting investor confidence.